42,743 Shares in Talis Biomedical Co. (NASDAQ:TLIS) Purchased by BML Capital Management LLC

BML Capital Management LLC bought a new position in shares of Talis Biomedical Co. (NASDAQ:TLIS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 42,743 shares of the company’s stock, valued at approximately $318,000.

Separately, Citigroup Inc. acquired a new stake in Talis Biomedical during the third quarter worth about $30,000. Institutional investors and hedge funds own 43.77% of the company’s stock.

Talis Biomedical Stock Up 0.6 %

Talis Biomedical stock opened at $9.05 on Wednesday. Talis Biomedical Co. has a 52 week low of $4.35 and a 52 week high of $9.32. The business’s 50-day moving average price is $8.57 and its 200 day moving average price is $7.59.

Talis Biomedical (NASDAQ:TLIS) last posted its earnings results on Thursday, March 28th. The company reported ($7.39) EPS for the quarter. The company had revenue of $0.20 million for the quarter. Talis Biomedical had a negative return on equity of 69.49% and a negative net margin of 2,905.67%.

Talis Biomedical Company Profile

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B.